title: Two novel Tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce Tau protein pathology.
abstract: Aggregated Tau proteins are hallmarks of Alzheimer disease and other tauopathies. Recent studies from our group and others have demonstrated that both active and passive immunizations reduce Tau pathology and prevent cognitive decline in transgenic mice. To determine the efficacy and safety of targeting the prominent 396/404 region, we developed two novel monoclonal antibodies (mAbs) with distinct binding profiles for phospho and non-phospho epitopes. The two mAbs significantly reduced hyperphosphorylated soluble Tau in long term brain slice cultures without apparent toxicity, suggesting the therapeutic importance of targeting the 396/404 region. In mechanistic studies, we found that neurons were the primary cell type that internalized the mAbs, whereas a small amount of mAbs was taken up by microglia cells. Within neurons, the two mAbs were highly colocalized with distinct pathological Tau markers, indicating their affinity toward different stages or forms of pathological Tau. Moreover, the mAbs were largely co-localized with endosomal/lysosomal markers, and partially co-localized with autophagy pathway markers. Additionally, the Fab fragments of the mAbs were able to enter neurons, but unlike the whole antibodies, the fragments were not specifically localized in pathological neurons. In summary, our Tau mAbs were safe and efficient to clear pathological Tau in a brain slice model. Fc-receptor-mediated endocytosis and the endosome/autophagosome/lysosome system are likely to have a critical role in antibody-mediated clearance of Tau pathology.
authors.affiliation: From the Departments of Neuroscience and Physiology and.
authors.forename: Jiaping
authors.initials: J
authors.lastname: Gu
authors.forename: Erin E
authors.initials: EE
authors.lastname: Congdon
authors.forename: Einar M
authors.initials: EM
authors.lastname: Sigurdsson
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy / Q000235:genetics / Q000276:immunology* / Q000473:pathology; D000818:Animals; D058846:Antibodies, Monoclonal, Murine-Derived / Q000276:immunology* / Q000494:pharmacology; D011992:Endosomes / Q000276:immunology / Q000473:pathology; D007140:Immunoglobulin Fab Fragments / Q000276:immunology* / Q000494:pharmacology; D008247:Lysosomes / Q000276:immunology / Q000473:pathology; D051379:Mice; D008822:Mice, Transgenic; D008954:Models, Biological; D009474:Neurons / Q000276:immunology* / Q000473:pathology; D010766:Phosphorylation / Q000235:genetics / Q000276:immunology; D016875:tau Proteins / Q000235:genetics / Q000276:immunology*
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D007140:Immunoglobulin Fab Fragments; C054369:MAPT protein, human; D016875:tau Proteins
keywords: Alzheimer Disease; Antibodies; Autophagosomes; Endosomes; Immunotherapy; Lysosomes; Phosphorylation; Tau